title: Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
abstract: We immunohistochemically analyzed kallikrein 4 protein (hK4) expression in patients with epithelial ovarian carcinoma (181 malignant effusions and 103 solid carcinoma lesions). Expression of hK4 was also studied in 32 effusions using immunoblotting. Carcinoma cells expressed hK4 in 144 (79.6%) of 181 effusions and 85 (82.5%) of 103 solid tumors. Expression was seen in 51% or more of tumor cells in 70 effusions but often was limited to 5% or fewer cells in solid tumors (P = .009, primary tumors vs effusions; P = .002, metastases vs effusions). Immunoblotting showed hK4 expression in 31 of 32 specimens. Stromal cell hK4 expression, seen in 48 (46.6%) of 103 lesions, was significantly higher in primary tumors than metastases (26/43 vs 22/60, P = .019). hK4 expression in tumor cells was significantly lower in International Federation of Gynecology and Obstetrics stage IV than stage III tumors (P = .004, all lesions; P = .012, primary tumors). hK4 expression in carcinoma cells was associated with longer overall survival (not significant; P = .14, peritoneal effusions). hK4 is expressed widely in ovarian carcinoma; levels in carcinoma cells are highest in effusions, which might be related to loss of stromal contribution and/or altered microenvironment. hK4 expression in carcinoma cells of effusions or solid tumors does not predict survival.
authors.affiliation: Department of Pathology, the Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Ben
authors.initials: B
authors.lastname: Davidson
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Xi
authors.forename: Tove Irene
authors.initials: TI
authors.lastname: Klokk
authors.forename: Claes G
authors.initials: CG
authors.lastname: Tropé
authors.forename: Anne
authors.initials: A
authors.lastname: Dørum
authors.forename: Marit
authors.initials: M
authors.lastname: Scheistrøen
authors.forename: Fahri
authors.initials: F
authors.lastname: Saatcioglu
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001202:Ascitic Fluid / Q000378:metabolism* / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D016066:Pleural Effusion, Malignant / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D015854:Up-Regulation
chemical_list: D007610:Kallikreins; C120801:kallikrein 4